Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer

Radiotherapy and Oncology

Volumn 90, Issue 2, 2009, Pages 172-176

  Pryor, David I ^a   Porceddu, Sandro V ^a,b   Burmeister, Bryan H ^a,b   Guminski, Alex ^a,b   Thomson, Damien B ^a,b   Shepherdson, Kristine ^a   Poulsen, Michael ^b,c  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c Department of Radiation Oncology Mater Centre ^*  (Australia)

Author keywords

Cetuximab; Head and neck; Radiotherapy; Skin; Toxicity

Indexed keywords

CETUXIMAB; DOXYCYCLINE; INTRASITE; UNCLASSIFIED DRUG; VALNOCTAMIDE;

ACNE; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONJUNCTIVITIS; DERMATITIS; DESQUAMATION; DISEASE EXACERBATION; DRUG WITHDRAWAL; DYSPHAGIA; FEMALE; HEAD AND NECK CANCER; HUMAN; HYPOPHARYNX CANCER; LARYNX CANCER; LOADING DRUG DOSE; LUNG CANCER; MALE; MUCOSA INFLAMMATION; OROPHARYNX CANCER; PATIENT COMPLIANCE; PLEURA EFFUSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; SKIN BLEEDING; SKIN TOXICITY; SKIN ULCER; SQUAMOUS CELL CARCINOMA; STOMATITIS; TIME SERIES ANALYSIS; TREATMENT PLANNING; URTICARIA; WOUND DRESSING;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DRUG ERUPTIONS; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; MALE; MIDDLE AGED; OTORHINOLARYNGOLOGIC NEOPLASMS; RADIODERMATITIS; RADIOTHERAPY DOSAGE;

EID: 59649119961     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2008.09.018     Document Type: Article

References (20)

1. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
2. Curran D., Giralt J., Harari P.M., and Ang K. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 25 (2007) 2191-2197
3. Budach W., and Bölke E. Homey B: severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med 357 (2007) 514-515
4. Mydin A.R., and Armstrong J.G. Acneiform rash secondary to cetuximab plus head and neck radiotherapy. Radiother Oncol 85 (2007) 171
5. Berger B., and Belka C. Severe skin reaction secondary to concomitant radiotherapy plus cetuximab. Radiat Oncol 3 (2008) 5
6. Bolke E., Gerber P., et al. Development and management of severe cutaneous side effects in head-and-neck cancer patients during concurrent radiotherapy and cetuximab. Strahlenther Onkol 184 (2008) 105-110 Feb
7. Lord H.K., Junor E., and Ironside J. Cetuximab is effective, but more toxic than reported in the Bonner trial. Clin Oncol (R Coll Radiol) 20 (2008) 96 Feb
8. Fu K.K., Pajak T.F., Trotti A., et al. A radiation therapy oncology group (RTOG) phase iii randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 48 (2000) 7-16
9. Bourhis J., Lapeyre M., Tortochaux J., et al. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. J Clin Oncol 24 (2006) 2873-2878
10. Calais G., Alfonsi M., Bardet E., et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 91 (1999) 2081-2086
11. Wendt T.G., Grabenbauer G.G., Rodel C.M., et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 16 (1998) 1318-1324
12. Withers H.R., Taylor J.M.G., and Maciejewski B. The hazard of accelerated tumor clonogene repopulation during radiotherapy. Acta Oncol 27 (1988) 131-146
13. Bernier J., Bonner J., Vermorken J.B., et al. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 19 (2008) 142-149
14. Segaert S., and Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 16 (2005) 1425-1433
15. Lacouture M.E. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6 (2006) 803-812
16. Galimont-Collen A.F., Vos L.E., Lavrijsen A.P., et al. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer 43 (2007) 845-851
17. Hu J., Sadeghi P., Pinter-Brown L., et al. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 56 (2007) 317-326
18. El-Abaseri T.B., and Hansen L.A. EGFR activation and ultraviolet light-induced skin carcinogenesis. J Biomed Biotechnol (2007) 97939
19. El-Abaseri T.B., Putta S., and Hansen L.A. Ultraviolet irradiation induces keratinocyte proliferation and epidermal hyperplasia through the activation of the epidermal growth factor receptor. Carcinogenesis 27 (2006) 225-231
20. Peter R.U., Beetz A., Ried C., et al. Increased expression of the epidermal growth factor receptor in human epidermal keratinocytes after exposure to ionizing radiation. Radiat Res 136 (1993) 65-70